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Abstract: Iron overloading disorders linked to mutations in ferroportin have diverse phenotypes
in vivo, and the effects of mutations on ferroportin in vitro range from loss of function (LOF) to gain
of function (GOF) with hepcidin resistance. We reviewed 359 patients with 60 ferroportin variants.
Overall, macrophage iron overload and low/normal transferrin saturation (TSAT) segregated with
mutations that caused LOF, while GOF mutations were linked to high TSAT and parenchymal
iron accumulation. However, the pathogenicity of individual variants is difficult to establish
due to the lack of sufficiently reported data, large inter-assay variability of functional studies,
and the uncertainty associated with the performance of available in silico prediction models. Since
the phenotypes of hepcidin-resistant GOF variants are indistinguishable from the other types of
hereditary hemochromatosis (HH), these variants may be categorized as ferroportin-associated HH,
while the entity ferroportin disease may be confined to patients with LOF variants. To further improve
the management of ferroportin disease, we advocate for a global registry, with standardized clinical
analysis and validation of the functional tests preferably performed in human-derived enterocytic
and macrophagic cell lines. Moreover, studies are warranted to unravel the definite structure of
ferroportin and the indispensable residues that are essential for functionality.
Keywords: SLC40A1; ferroportin; iron overload; non-HFE; ferritin; hemochromatosis
1. Introduction
Hereditary hemochromatosis (HH) type 4 or ferroportin disease (OMIM-code: 606069
Orphanet-code: 139491) is associated with variants in SLC40A1 and inherited in an autosomal-dominant
manner. Since 1999, ferroportin disease was classified into two entities [1–3], based on experimental
in vitro models of genetic variants found in patients [4–10]. Classical ferroportin disease (Type 4A) is
associated with loss-of-function (LOF) variants with diminished cell surface expression of ferroportin
and lower iron export capacity, and is characterized by macrophage iron retention and iron restriction
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for erythropoiesis. It is clinically recognized by the presence of high serum ferritin concentrations with
low to normal transferrin saturation (TSAT) and poor tolerance to phlebotomy. Non-classical (atypical,
type 4B) ferroportin disease is associated with gain-of-function (GOF) variants that render ferroportin
protein resistant to hepcidin, resulting in continued iron export, and leading to a phenotype that
mimics classical HFE HH characterized by parenchymal (hepatocellular) iron overload with elevated
serum ferritin and TSAT.
Systematic and narrative reviews on ferroportin disease revealed the great variety in iron
parameters among patients with ferroportin variants and emphasize the poor correlation between iron
export capacity in functional studies and clinical characteristics (phenotype) [7,9–11] and question the
pathogenicity of various variants [8,12].
To better guide the management of this disorder, a better understanding of the clinical and
biochemical features of ferroportin disease and its underlying pathological mechanisms is required.
In this report, we evaluated and describe clinical and laboratory data of patients reported between
1999 and June 2019, in whom the identified ferroportin variant was assumed to be associated with
the defined state of iron overload. The relation between patient’s clinical features and the functional
in vitro features of underlying variants is assessed in context of current knowledge on the function and
structure of ferroportin and its regulatory mechanisms. We comment on the shortcomings of describing
the phenotype based on case and family reports, and review the limited applicability of functional
studies and available in silico prediction models to determine pathogenicity. We recommend the
institution of a global registry with a (1) standardized diagnostic protocol, (2) validated functional tests,
and (3) studies to establish the definite secondary and tertiary structure of ferroportin and residues
involved in its binding with hepcidin for ubiquitination and to ferroportin for iron transport.
2. Methods
2.1. Data Collection and Selection
Identification, Demographic Characteristics, and Iron Parameters
A literature search was done using Medline and Embase (searching strategy: #1 (SLC40A1 or
ferroportin or IREG or IREG-1 or FPN or FPN1 or non-HFE hemochromatosis), #2 (mutation or variant)
from 1999 to June 2019. Papers with only an abstract in English were also selected. We included all the
cases (including family studies) of ferroportin variants that are associated with unexplained elevated
serum ferritin concentration. Since the aim of this analysis was to evaluate the relation between the
clinical features and the functional in vitro characteristics in experimental cell lines of the various
potentially pathogenic variants, we excluded variants for which these functional studies have not been
performed, e.g., variants in promoter and untranslated regions, splicing variants as well as variants
leading to synonymous amino acids such as Iso109Iso, Leu129Leu, and Val221Val [13–17]. In addition,
we excluded patients with previously established neutral or (possibly) iron-modifying polymorphisms
with a variant population frequency > 1%, such as the African Gln248His variant and variants in
residues Leu348 and Leu384 [7,18–21].
Only patients with reported numerical value of at least transferrin saturation (TSAT) or
ferritin concentration were selected. Demographic features, presenting symptoms, blood test
results (hemoglobin (Hb), mean corpuscular volume (MCV), serum iron, TSAT, ferritin, and alanine
aminotransferase (ALT)), hepatic iron content and hepatic histology, data on tolerability of phlebotomy
(including the amount of iron removed), and the presence of p.Cys282Tyr and p.His63Asp HFE variants
and other potential confounders, such as alcohol consumption and signs of metabolic syndrome, were
collected. Organ iron accumulation as assessed by MRI and histologic examination was evaluated.
Hepatic damage was histologically scored using the Meta-analysis of Histological Data in Viral Hepatitis
(METAVIR) score (0 = no fibrosis, 1 = mild fibrosis (portal fibrosis without septa), 2 = moderate
fibrosis (portal fibrosis and few septa), 3 = severe fibrosis (numerous septa without cirrhosis), and 4
= cirrhosis). Differences between categorical variables were compared with the Chi-square test with
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Yates correction while the comparison of continuous variables was done with the Mann-Whitney U-test
and Student’s–t -test of independent means. A two-sided p-value < 0.05 was considered significant.
The correlation between variables was determined by the Pearson correlation coefficient.
2.2. Variant Classification Based on Functional In Vitro Studies
Functional studies on iron export and/or ferroportin expression were performed in cell lines
transfected with the ferroportin protein variant. We reviewed the reported functional studies on
iron export capacity and ferroportin expression that were performed in cell lines transfected with the
wild-type and the variant ferroportin protein. We assigned a variant as an LOF variant when the iron
export capacity was significantly reduced, in comparison to the wild-type (WT) protein. The variant
was assigned as a GOF variant when the iron transport capacity was preserved. When the addition of
hepcidin significantly inhibited the iron export capacity and/or ferroportin expression, the variant was
defined as hepcidin-sensitive, and the variant was hepcidin-resistant in the absence of a modulating
effect of hepcidin. A variant was scored as “non-classified” when no relevant functional data were
available, and as “conflicting” when data on the hepcidin effect were inconsistent or inconclusive.
2.3. Bioinformatics Prediction Software Analysis
To assess co-segregation in multiple affected family members, the simplified method of segregation
analysis (SISA) was applied [22,23] and classified according to recent recommendations to define
co-segregation to fit the guidelines of the American College of Medical Genetics and Genomics
and the Association for Molecular Pathology (ACMG-AMP) [22,24]. Briefly, to determine the
co-segregation we used the classification suggested by Jarvik et al. and the method to calculate
the probability that the phenotype of a variant carrier is caused by chance rather than genotype,
as suggested by Moller et al. [22,23]. This probability is described as (1/2)n, wherein n is the
number of informative meiosis and will be the number of the carriers with the affected phenotype
of interest and all the carriers in between them, minus one. The genome aggregation data base
(gnomAD), was applied to determine of the allele frequency of a variant. In order to further
determine the potential pathogenicity of the various variants three commonly used algorithms were
applied [25]. Polyphen2 predicts the impact of amino acid substitution on the structure and function
of human protein using physical and comparative considerations [26]. The method “Sorts intolerant
from Tolerant” (SIFT) (http://www.blocks.fhcrc.org/sift/SIFT.html) classifies non-synonymous single
nucleotide polymorphisms on the basis of the evolutionary conservation of amino acids within protein
families [27]. Align-GVGD predicts variants in the query sequence based on a combination of Grantham
Variation (GV) which measures the evolutionary variation at a particular position in the alignment and
Grantham Deviation (GD), measuring the biochemical difference between the reference and amino
acid encoded by the variant [28].
3. Evaluation and Analysis
3.1. Description of the Phenotype of Patients (Including Related Family Members) in Relation Findings in
Functional Studies
3.1.1. Patients Characteristics
Ferroportin Disease Occurs in Different Parts of the World and Has no Specific Symptoms
We retrieved 359 individuals with 60 variants (59 missense variants and one deletion) in the
ferroportin protein (Table 1). The reported patients, were predominantly male and of European descent.
When reported, fatigue and arthralgia were the major presenting symptoms. Overall, patients had
normal Hb and MCV with a serum iron level and TSAT at the upper range of normal and moderately
elevated ferritin levels.
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Table 1. Patient Characteristics. MCV: mean corpuscular volume, TSAT: transferrin saturation.
Characteristics n Value (Median) Range
Patients 359
Probands 68
Relatives from probands 191
Individual patients 88
Gender 342
Female 131
Male 211
Age (years) 322 41 2–87
Continent 352
Europe 258
North–South America 37
Asia 44
Australia/Oceania 13
Presenting clinical symptoms 71
Fatigue 34
Elevated liver enzymes / hepatomegaly 30
Joint complaints/arthralgia 36
Miscellaneous 47
Referral because of high ferritin level 131
Hematological Parameters
Hemoglobin (g/dL)#
Female 60 13.1 7.5–16.3
Male 92 15.0 6.5–18.4
MCV (fl)
Female 38 91 77–107
Male 46 91 70–108
Serum iron (µmol/L)
Female 34 20.9 6.7–94.0
Male 56 26.3 6.2–86.0
TSAT (%)
Female 116 31.5 2.0–100.0
Male 180 38.0 7.0–104.0
Ferritin (µg/L)
Female 122 1026 4–8943
Male 201 1514 12–18695
Iron Parameters are Determined by Gender and Age. #Significant difference between females and males (p < 0.05,
also after correcting for multiple testing according to Bonferroni (<0.01).
Women had significantly lower Hb, TSAT, and serum ferritin concentration (Table 1). There
was a weak correlation between age and TSAT (r = 0.1796) and serum ferritin (r = 0.3461) (Figure
S1a–c). Probands were significantly older than affected family members (45.5 versus 34 years) with
significantly higher (1896 versus 948 µg/L) serum ferritin levels (Table S1). Ten percent (20/191) of
affected family’s members (6/14 males/females, median age 42 years) had no biochemical signs of iron
overload (ferritin level ≤ 200 µg/L and normal TSAT).
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Modification by Additional Hereditary and Acquired Conditions
We found no effect of the presence of p.Cys282Tyr (13 heterozygotes) and p.His63Asp
(35 heterozygotes, five homozygotes) HFE variants on iron parameters (Table S2). In only 84 patients,
the current alcohol consumption was reported without demonstrable effect (Table S3). The reported
clinical data were insufficient for the proper determination of the presence of metabolic syndrome to
explore its modifying effect.
3.2. Relation between In Vitro Functional Studies of Ferroportin Variants on Clinical Features
We identified 27 different GOF variants (110 patients), 21 LOF variants (205 patients), and 12
unclassified variants (33 patients) (Table 2). A total of 355 cases involved heterozygosity for ferroportin
variants. One homozygous Gly204Ser GOF variant was reported in a 52-year-old female with ferritin
concentration of 5236 µg/L, TSAT of 100%, and symptoms of hepatic fibrosis revealed by radiology [15].
A patient with homozygosity for the GOF variant Arg561Gly had biochemical signs of severe iron
overload reflected by a serum ferritin of 2750 µg/L and TSAT of 84% [29].
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Table 2. Functional and phenotypical characteristics of 359 patients with 60 ferroportin variants. GOF: gain of function, LOF: loss of function.
Protein Iron Export Hepcidin Effect on TSAT
Variant Expression Capacity Expression Export Capacity Fate of Hepcidin Patients (n) Normal High Reference%
Tyr64Asn PM = no no ↓↓ubiquitination/uptake 8 - 8 [11,30–36]
Cys326Ser PM = no no ↓binding/nouptake 7 - 6 [30,32,34,37,38]
Cys326Tyr PM = no no ↓/no uptake 4 - 4 [8,31,34,35,39–44]
Tyr333His PM = no no 5 - 5 [45]
Tyr501Cys PM = no no ↓binding 7 2 5 [30,33,46]
Asp504Asn PM = no no ↓binding/uptake 2 - 2 [8,30]
His507Arg PM = no no ↓↓ubiquitination 4 - 4 [30,41,47]
Sum: 7 GOF Hepcidin Resistant 37 2 34
ILe180Thr PM = yes – normal uptake 3 2 1 [8,48,49]
Thr230Asn PM = yes – normal uptake 1 1 - [8]
Met266Thr PM = yes – normal uptake 1 1 - [8]
Leu345Phe PM = yes – normal uptake 1 1 - [8]
Ile351Val PM = yes – ↑uptake 1 1 - [8]
Pro443Leu PM = yes – ↑uptake 1 - - [8]
Arg561Gly PM = yes – normal uptake 4 1 2 [8,29,50]
Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3
Ala69Thr PM = – ↓! – 4 2 2 [42,51,52]
Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53]
Asn144Asp PM =# conflicting no# ↓binding/uptake 2 - 1 [30–32,35,54]
Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59]
Asn144Thr PM = conflicting yes# ↓uptake 1 - 1 [6,31,32,34,60]
Gln182His PM = conflicting yes normal uptake 2 1 - [55,56,61]
Gly204Arg~ PM = no$ no$ – 1 - 1 [51]
Gly204Ser PM = conflicting no# ↓ubiquitination 14 4 10 [9,11,15,30]
Ser209Leu PM = no$ no$ – 7 7 - [62,63]
Asp270Val PM =# yes ↓!
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Arg88Gly IC/PM ↓ yes -- -- 7 3 3 [8,11,82] 
Leu129Pro PM ↓ yes ↓yes -- 5 3 2 [83] 
Arg178Gln PM ↓ yes -- -- 26 17 - [75,82,84,85] 
Asn185Asp PM ↓ yes -- -- 19 4 6 [9,11,86] 
Sum: 4 LOF Hepcidin Sensitive  57 27 11  
Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] 
Gly80Ser ↓PM ↓& not reliable@ not reliable@ normal uptake& 24 15 3 [8,57,73,87,88,91,92] 
Ile152Phe PM ↓ ↓ ↓ -- 2 - - [39,93] 
Asp157Gly IC/PM ↓ conflicting no& -- 4 3 1 [8,34,55,56,61] 
Asp157Tyr ↓PM ↓ -- -- -- 2 1 1 [8,94] 
Trp158Cys IC ↓ not reliable@ not reliable@ -- 4 4 - [41,62] 
Trp158Leu IC ↓ not reliable@ not reliable@ -- 2 2 - [11] 
Asn174Ile IC/PM ↓ conflicting not reliable@ ↓uptake 3 1 2 [34,39,46,87,88] 
Leu233Pro IC/↓PM ↓ not reliable@ -- -- 3 1 2 [8,55,93] 
Gly323Val IC/PM ↓ conflicting not reliable@ ↓↓uptake 1 - - [34,55,56,61] 
Arg489Lys IC ↓ -- -- -- 6 4 - [40] 
Gly490Ser ↓PM ↓ -- -- -- 3 2 1 [8,35,82] 
Sum: 12 LOF Uncertain/Conflicting/Unknown  80 48 21  
Tyr64His      1 - 1 [95] 
Gly80Val      2 2 - [80] 
Arg88Thr      7 3 4 [48] 
Asp157Ala      5 2 3 [96–98] 
Asp157Asn      5 5 - [45,53] 
Ala232Asp      2 2 - [99] 
Lys240Glu      1 - 1 [100] 
Gly267Asp      1 1 - [80] 
Cys326Phe      1 - 1 [101] 
Gly468Ser      3 3 - [102] 
Arg489Ser      4 2 2 [94,103] 
Val511Ile      1 - 1 [45] 
Sum: 12 Non-Classified    33 20 13  
         
Sum: 60     359 200 114  
%reference before the comma refers to reports on functional data; reference after the comma points to reports on clinical data; PM plasma membrane; IC intracellular; = 
comparable; -- no data available; ~ discrepancy in the classification with respect to the original report [51], ! dependent n the dose of hepcidin and time of exposure; # data not 
fully consistent; $ not strongly established; ^ In one study [104], this variant had diminished iron efflux; ↓↓ severe; ↓moderate/mild, ↓ borderline impaired; @ interpretation is 
hampered since the variant is mainly localized intracellularly in the experiments; & data of de Domenico et al. [55,87] were disregarded in view of an unexpected discrepancy 
with other reports.
ubiquitination 2 1 1 [14,30,64]
Arg296Gln~ PM = no$
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– 1 1 - [51]
Ser338Arg PM = yes ↓!
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ubiquitination 1 - 1 [6,30,65]
Arg371Gln IC/PM = no yes – 1 1 - [11]
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Table 2. Cont.
Protein Iron Export Hepcidin Effect on TSAT
Variant Expression Capacity Expression Export Capacity Fate of Hepcidin Patients (n) Normal High Reference%
Sum: 13 GOF Uncertain/Conflicting/Unknown 61 32 27
Asp84Glu – ↓ no – – 1 - - [43]
Val162del IC/↓PM ↓ no no ↓↓uptake 50 39 2 [6,8,35,43,51,55,56,66–79]
Asp181Asn PM ↓ no no – 6 6 - [51]
Asp181Val ↓PM ↓ no no – 10 10 - [8,42,46,80]
Gly490Asp IC/PM ↓ no no no uptake 12 9 3 [8,34,55,81]
Sum: 5 LOF Hepcidin Resistant 79 64 5
Arg88Gly IC/PM ↓ yes – – 7 3 3 [8,11,82]
Leu129Pro PM ↓ yes
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yes – 5 3 2 [83]
Arg178Gln PM ↓ yes – – 26 17 - [75,82,84,85]
Asn185Asp PM ↓ yes – – 19 4 6 [9,11,86]
Sum: 4 LOF Hepcidin Sensitive 57 27 11
Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90]
Gly80Ser ↓PM ↓& not reliable@ not reliable@ normal uptake& 24 15 3 [8,57,73,87,88,91,92]
Ile152Phe PM ↓ ↓ ↓ – 2 - - [39,93]
Asp157Gly IC/PM ↓ conflicting no& – 4 3 1 [8,34,55,56,61]
Asp157Tyr ↓PM ↓ – – – 2 1 1 [8,94]
Trp158Cys IC ↓ not reliable@ not reliable@ – 4 4 - [41,62]
Trp158Leu IC ↓ not reliable@ not reliable@ – 2 2 - [11]
Asn174Ile IC/PM ↓ conflicting not reliable@ ↓uptake 3 1 2 [34,39,46,87,88]
Leu233Pro IC/↓PM ↓ not reliable@ – – 3 1 2 [8,55,93]
Gly323Val IC/PM ↓ conflicting not reliable@ ↓↓uptake 1 - - [34,55,56,61]
Arg489Lys IC ↓ – – – 6 4 - [40]
Gly490Ser ↓PM ↓ – – – 3 2 1 [8,35,82]
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Table 2. Cont.
Protein Iron Export Hepcidin Effect on TSAT
Variant Expression Capacity Expression Export Capacity Fate of Hepcidin Patients (n) Normal High Reference%
Sum: 12 LOF Uncertain/Conflicting/Unknown 80 48 21
Tyr64His 1 - 1 [95]
Gly80Val 2 2 - [80]
Arg88Thr 7 3 4 [48]
Asp157Ala 5 2 3 [96–98]
Asp157Asn 5 5 - [45,53]
Ala232Asp 2 2 - [99]
Lys240Glu 1 - 1 [100]
Gly267Asp 1 1 - [80]
Cys326Phe 1 - 1 [101]
Gly468Ser 3 3 - [102]
Arg489Ser 4 2 2 [94,103]
Val511Ile 1 - 1 [45]
Sum: 12 Non-Classified 33 20 13
Sum: 60 359 200 114
%reference before the comma refers to reports on functional data; reference after the comma points to reports on clinical data; PM plasma membrane; IC intracellular; = comparable; – no
data available; ~ discrepancy in the classification with respect to the original report [51], ! dependent on the dose of hepcidin and time of exposure; # data not fully consistent; $ not strongly
established; ˆ In one study [104], this variant had diminished iron eﬄux; ↓↓ severe; ↓moderate/mild,
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3.2.1. Clear Distinct Phenotypical Features in Patients with GOF and LOF Variants
Patients with GOF variants had significantly lower ferritin (755 µg/L versus 1595 µg/L)
concentration (Table 3) and higher serum iron (36.0 µmol/L versus 17.5 µmol/L) concentration and
TSAT (62% versus 32%) than patients with LOF variants. Inter-individual variation in TSAT levels
was high in both LOF and GOF patients (Figure 1). In contrast to previous reports [7,105] and the
prevailing opinion [10], patients with LOF and GOF variants were found to have a comparable Hb and
prevalence of anemia (according to the World Health Organization criteria). While hepatic iron content
was similar in patients with LOF and GOF variants, patients with LOF variants display iron deposition
predominantly in macrophages (Kupffer cells), while the iron in GOF patients is predominantly present
in hepatocytes, and is associated with more hepatic damage as reflected by the significantly higher
serum ALT and amount of fibrosis (scored according to the METAVIR scale).
Table 3. Phenotypic features by ferroportin functional gene variant.
Phenotypic Features Gain-of-Function
(n = 110)
Loss-of-Function
(n = 216)
p
Age (years) n = 93 n = 203 0.032&
median (range) 46 (2–80) 36 (6–87) 0.055&&
Gender (n)
Female 35 82
Male 66 126 ns
Hb (g/dL) n = 39 n = 104
median (range) 14.4 (9.5–16.5) 14.4 (10.1–18.4) ns
Anemia
Yes 4 14
No 35 90 ns
MCV (fl) n = 29 n = 50
median (range) 93 (70–108) 91 (73–98) ns
Serum iron (µmol/L) n = 45 n = 51 0.0002&
median (range) 36.0 (8.0–74.0) 15.7 (6.2–94.0) 0.00017&&
TSAT (%) n = 105 n = 174 < 0.0001&
median (range) 62 (2–104) 32 (5–99) < 0.0001&&
Ferritin (µg/L) n = 100 n = 208 < 0.0001&
median (range) 755 (4–15000) 1595 (24–21665) 0.0013&&
Iron Removed (g) n = 10 n = 31
median (range) 10.2 (2–24.4) 8.0 (1.6–80.0) ns
Tolerance to Phlebotomy (n)
Good 16 38
Poor 2 13 ns
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Table 3. Cont.
Phenotypic Features Gain-of-Function
(n = 110)
Loss-of-Function
(n = 216)
p
HIC(µg/g) n = 19 n = 53
median (range) 11718 (925–38665) 10052 (307–58590) ns
Grade of fibrosis
0–2 14 20
3–4 10 2 0.012
Hepatic Iron distribution
Hepatic (predominant) 18 7 < 0.00001@
Macrophagic (predominant) 0 28
Mixed 10 16 < 0.00001@@
ALT (IU/L) n = 31 n = 48 0.0026&
median (range) 52.0 (14.0–304.0) 29.5 (6.0–98.0) 0.004&&
HIC, hepatic iron content; ALT, alanine aminotransferase. &Mann–Whitney U-test, &&Student’s t-test of independent
means, p is significant < 0.0033 when corrected for multiple testing according to Bonferroni. @difference between
hepatic and macrophagic, @@difference between hepatic, macrophagic, and mixed.
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Figure 1. Box plots (Whiskers: min to max) of transferrin saturation (TSAT) in individuals with 
ferroportin variants. Only the variants with at least five reported TSAT levels in patients are included. 
Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants; 
Green: LOF without or conflicting data about hepcidin sensitivity; Light blue: LOF hepcidin-resistant 
variants; Blue: LOF hepcidin-sensitive variants; Gray: No data available.
Figure 1. Box plots (Whiskers: min to max) of transferrin saturation (TSAT) in individuals with
ferroportin variants. Only the variants with at least five reported TSAT levels in patients are included.
Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants;
Green: LOF without or conflicting data about hepcidin sensitivity; Light blue: LOF hepcidin-resistant
variants; Blue: LOF hepcidin-sensitive variants; Gray: No data available.
Long-term follow-up information and data to determine a difference in clinical course between
GOF and LOF variant patients are limited [12,106]. We found three documented deaths related to
ferroportin disease: fatal hepatocellular carcinoma in one GOF and one LOF variant patient [48,82].
One patient with a GOF mutation died of multiorgan failure due to widespread iron deposition [50].
3.2.2. Strong Association of Hepcidin Sensitivity of Ferroportin Functional Gene Variants with Serum
Iron Parameters
In vitro hepcidin sensitivity studies were performed in 45 variants. We identified seven
hepcidin-resistant and seven hepcidin-sensitive GOF variants, and five hepcidin-resistant and four
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hepcidin-sensitive LOF variants (Table 2). Twelve LOF and 13 GOF variants were designated as
uncertain/conflicting/unknown, including those variants with partial resistance or sensitivity.
Patients with hepcidin-resistant LOF variants had significantly lower TSAT (27% versus 35%) and
serum iron (14.1 µmol/L versus 28.7 µmol/L) but higher ferritin (1810 µg/L versus 1066 µg/L) than
patients with a hepcidin-sensitive LOF variant (Table S4, Figure 2).
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Figure 2. Iron parameters for the different ferroportin variants. Mean (+ SD) of (A) serum iron,
(B) transferrin saturation, and (C) ferritin as measured in patient samples for the function of
variant (LOF = loss-of-function, GOF = gain-of-function) and the effect of hepcidin (hep resistant
= hepcidin-resistant, hep sensitive = hepcidin-sensitive) on the iron transport capacity, as assessed by
in vitro functional tests. TSAT = transferrin saturation. The Student’s t-test was applied to determine
the difference between serum iron and TSAT, while the Mann–Whitney U-test test was applied for
ferritin. Displayed p values, serum iron, and TSAT are according to the Student’s t-test. Displayed p
values ferritin according to the Mann–Whitney U-test.
However, patients with hepcidin-resistant GOF variants had highly significant higher serum iron
(44.0 µmol/L versus 14.0 µmol/L) and TSAT (92% versus 28%) and lower ferritin (642 µg/L versus
Pharmaceuticals 2019, 12, 132 12 of 29
1810 µg/L) concentration than patients with hepcidin-resistant LOF variants (Table S5, Figure 2).
All seven patients with a hepatocyte predominant iron deposition carried a hepcidin-resistant GOF
variant, while all nine patients with a macrophage predominant iron deposition had a hepcidin-resistant
LOF variant.
3.3. Therapeutic Considerations
In patients with primary iron overload, phlebotomy is the cornerstone of treatment. In 93 of
102 patients who were reported to be phlebotomized, the tolerance of the phlebotomy was reported.
A total of 73 patients tolerated phlebotomy without side effects. In 17 of 20 patients with poor tolerance
to phlebotomy, the cause of the intolerance could be analyzed. In 12 of the 14 patients with intolerance
to phlebotomy due to the development of early anemia, phlebotomy could be continued by the
application of a less intensive phlebotomy schedule. In one patient, anemia subsided despite the
continuation of the same regimen. In three additional patients, the administration of erythropoietin
resulted in an increase of Hb and continuation of the phlebotomy regimen [59,107]. In two patients,
phlebotomy was discontinued because of the occurrence of anemia. Treatment with deferasirox
resulted in a dramatic decrease in serum ferritin concentration in two patients, but was not successful
in another [52,76,96].
In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were
not less tolerant to phlebotomy than patients with GOF variants (Table 3). Nevertheless, in five of 22
(23%) patients with hepcidin-resistant LOF variants the reported phlebotomy was poorly tolerated
(Table S5) due to early anemia.
4. Critical Annotations on Pathogenicity of Variants
In Table 4, we depicted the potential pathogenicity of the various variants derived from available
clinical, epidemiological, and genetic data from the original reports. We scored the likelihood of
the pathogenicity of a variant based on the available data from the genome aggregation data base
(gnomAD), data derived from the functional tests, at the molecular level in context of the current
knowledge of the function and structure of the ferroportin molecule, and based on three in silico
predicting models.
Table 4. Likelihood of pathogenicity derived from the reported data, and current databases and
prediction models.
In silico Prediction
Variant Pheno-Type Co-Segregation VO/Controls gnomAD Functional Molecular Poly-phen2 SIFT Align-GVGD
Tyr64Asn +++ +++ 0/100 ++++ ++ ++ 0 0
Tyr64His +++& ++ ++ 0 0
Ala69Thr +++& 0 ++ 0 ++ + 0
Val72Phe + + +++ 0 ++ 0 0
Ala77Asp +++ ++,+++# 0/100 +++ 0 ++ + 0
Gly80Ser ++ 0/734 +++ + ++ + 0
Gly80Val ++ 0/100 + ++ + 0
Asp84Glu +++& ++ + ++ + 0
Arg88Gly +++ 0/734 ++ + ++ + 0
Arg88Thr ++ +++ 0/60 + ++ + 0
Leu129Pro 0 + ++++ 0 ++ + +++
Asn144Asp +++ +++ + ++ 0 0
Asn144His 0 +++ 0/200 +++ + + 0 0
Asn144Thr 0& 0/100 +++ + ++ 0 0
Ile152Phe +++ + +++ + ++ 0 0
Asp157Ala ++ ++ + ++ + 0
Asp157Asn ++ 0 + ++ 0 0
Asp157Gly +++ 0/80, 0/734 +++ + + 0 0
Asp157Tyr +++ 0/734 + + ++ + +
Trp158Cys +++ 0,+ 0/50 +++ 0 ++ + ++
Trp158Leu +++ +++ 0 + 0 0
Val162del ++ +,+++ 0/100, 0/103,
0/734
++++ 0 @ @ @
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Table 4. Cont.
In silico Prediction
Variant Pheno-Type Co-Segregation VO/Controls gnomAD Functional Molecular Poly-phen2 SIFT Align-GVGD
Asn174Ile +++ +++ + ++ + +++
Arg178Gln +++ 0-+++## ++ +++ ++ 0 0
Ile180Thr 0 0 0/100 7.076−5 ++ 0 ++ + +++
Asp181Asn ++ ++ + ++ + +
Asp181Val ++ +,++ 0/100, 0/734 ++ + ++ + +++
Gln182His +++ 0/80 +++ 0 ++ + +
Asn185Asp +++ +,+++ 0/50 + 0 ++ + +
Gly204Arg +++& ++ 0 ++ + +++
Gly204Ser + +++ 2/100 7.955−6 +++ 0 ++ 0 0
Ser209Leu 0 ++ 1.485−4 +++ 0 0 0 +
Thr230Asn 0& 0/734 1.096−4 ++ 0 + 0 0
Ala232Asp 0 4.95−5 0 + 0 +
Leu233Pro +++ 0 0/734 ++ 0 ++ + +++
Lys240Glu +++& 0/50 0 0 + 0
Met266Thr 0& 0/734 ++ 0 0 + 0
Gly267Asp ++& 0/100 4.382−5 0 + 0 0
Asp270Val + 4/100, 1/516 7.09−5 +++ 0 0 0 0
Arg296Gln 0& ++ 0 + 0 ++
Gly323Val +++& 0/80 +++ 0 ++ + +++
Cys326Phe +++& 0 ++ ++ 0 +
Cys326Ser +++ +++ ++++ +++ + 0 0
Cys326Tyr +++ 0/800 ++++ ++ + 0 0
Tyr333His +++ 0/40 ++ + ++ + +++
Ser338Arg +++& +++ 0 0 0 0
Leu345Phe 0& 0/734 ++ 0 ++ 0 0
Ile351Val 0& 0/734 2.125−5 ++ 0 0 0 0
Arg371Gln 0& 2.388−5 +++ 0 0 0 0
Pro443Leu 0& 0/734 5.87−4 ++ 0 0 0 0
Gly468Ser ++ 0 4.005−6 0 ++ 0 +
Arg489Lys +++ +++ 0/50 + + ++ + +++
Arg489Ser + 0/734 + ++ + +++
Gly490Asp +++ 0 0/734 ++++ 0 ++ 0 0
Gly490Ser +++ 0/734 + 0 ++ 0 0
Tyr501Cys + 0/200 3.184−5 ++++ +++ + 0 +
Asp504Asn +++ 0/734 ++++ +++ ++ 0 0
His507Arg +++ + 0/50 ++++ ++ ++ 0 0
Val511Ile +++& 0 ++ + ++
Arg561Gly + 0/734 1.638−3 ++ 0 0 0 0
Open space: no data available. Phenotype: bold: at least five patients; 0 = < 50%, + = 51–80%, ++ = 81–99%,
+++ =100% presence of an elevated TSAT in GOF patients and elevated ferritin in LOF patients. Variants in italic are
unclassified; + = elevated TSAT and/or ferritin (but not in all patients), ++ = elevated TSAT or ferritin in all patients,
+++ = elevated TSAT and ferritin in all patients. & only one reported patient. # enumeration of a limited number of
studies; ## range in multiple studies. Co-segregation from pedigrees in the original reports using the simplified
method of segregation analysis (SISA) according to the following scoring system: single family: 0 = no evidence,
+ = ≤1/8 (supporting), ++ = ≤ 1/16 (moderate), +++ = ≤ 1/32 (strong); bold: multiple family studies: 0 = no evidence,
+ = ≤ 1/4 (supporting), ++ = ≤ 1/8 (moderate), +++ = ≤ 1/16 (strong); all according to the recommendations of
Jarvik et al. [22] to define co-segregation as criteria to fit the ACMG-AMP guidelines [24]. VO/Controls: Variant
Occurrence in controls reported in the original reports. GnomAD: allele frequency derived from GnomAD data
base [25]; the variants for which no allele frequency are given are absent in the database and thus extremely rare.
Functional: + = effect of hepcidin not performed, ++ = effect of hepcidin established only on membrane expression
or iron transport, +++ = conflicting or unreliable results on the effect of hepcidin, with reported fate of hepcidin,
++++ = established effect of hepcidin on membrane expression and iron export with/without reported fate of
hepcidin; Bold = ≥ 3 independent studies. Molecular: 0 = variant present on a site without established role in
ferroportin molecule, + = variant present at a site potentially involved in the formation of the intracellular and
extracellular gate, internalization and degradation of the ferroportin molecule or at a site potentially involved in iron
binding or egress, ++ = variant present at a site with established function in hepcidin binding, +++ = variant present
at a site leading to established conformational changes in the structure of the ferroportin molecule as predicted in
the available three-dimensional (3D) models. In silico prediction: Polyphen 2: 0 = benign, + = possibly damaging,
++ = probably damaging; “Sorts intolerant from Intolerant” (SIFT): 0 = tolerated, + = deleterious; Align-GVGD:
0 = class 0, + = Class 15, ++ = Class 25 and 35, +++ = Class 55 and 65; @ = It is not possible to test deletions in
Polyphen2, SIFT, and Align-GVGD.
4.1. Shortcomings in Description of Clinical Phenotypes
The collected data to describe the clinical phenotype were derived from extensively documented
family studies to isolated patients with minimal reported clinical data as part of national surveys of
patients with iron overload. So, the available clinical, biochemical, radiological, and histological data
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were the most heterogenous. In addition, in family studies, relatives were more than 10 years younger
with a milder phenotype, including 11% with normal iron parameters. In many patients, a genetic
diagnosis was made after referral, and reported iron parameters may potentially have been affected
by previous phlebotomies. The demonstrated lack of effect on the presence of additional acquired
iron-modulating conditions must be interpreted with caution in view of insufficient reported data.
The presence of polymorphisms in ferroportin may affect the degree of iron overload in homozygotic
patients for p.Cys282Tyr variants in the HFE molecule [13]. The lack of effect of presence of HFE
variants on the iron parameters in our analysis is likely to be explained by the absence of patients with
homozygotic p.Cys282Tyr HFE variants.
The phenotype of a number of reported variants raised doubt on the pathogenicity of these
variants. An elevated TSAT is considered to be the hallmark of GOF variants. In 41 of 116 GOF patients,
TSAT was normal. Since 13 of them also had a ferritin level ≤ 200 µg/L, 11% of GOF patients had
normal serum iron parameters, especially patients with Asn144His (8/20 pts) and Val72Phe (2/5 pts)
variants. Also, 7/9 reported patients with the seven hepcidin-sensitive GOF variants had a normal TSAT.
The Gly204Ser GOF variant displayed evident pathologic iron parameters in a homozygous patient,
with normal iron parameters in the two heterozygous relatives, and four of 14 additional reported
patients had normal TSAT. Six of 197 LOF patients had normal reported ferritin level including 3/5
Leu129Pro variant patients. In a 10-year follow-up study of a proband and his father with a Arg489Ser
variant, the serum iron spontaneously decreased with a slight reduction in the MRI estimated HIC [12].
4.2. Shortcomings in Establishment of Pathogenicity
4.2.1. Co-Segregation with Disease in the Family
SISA was applicable for 26 variants and hampered by the small pedigrees in most reports. In 13
variants, there was no or only supporting evidence for pathogenicity; in nine variants, evidence was
moderate or strong, and for four variants, the score for pathogenicity was inconclusive (Table 4).
4.2.2. Variant Occurrence and Allele Frequency
In the original reports, variant occurrence in healthy controls was determined for 37 variants
in relatively small cohorts (range 40 to 734 persons) with an established occurrence of < 1/100 for
26 variants. In the genome aggregation data base (gnomAD, [25]), 213 missense variants were observed
with subsequent determination of the allele frequency. Of these, only 13 variants displayed clinical
symptoms to be reported and analyzed in the current review. Notably, 47/60 variants in our analysis
are so rare that the allele frequency is not depicted in gnomAD.
4.2.3. Limitations of Functional In Vitro Tests
In most of the transfection studies HEK293T, a human embryonic kidney cell line, was
used [6,8,11,31–33,35,39–42,46,55–57,83,87,93] and occasionally Xenophus oocytes, colon carcinoma
CaCo-2, or hepatoma HuH7 cell lines [6,57,66]. Protocols are not standardized. Iron loading was
done with 1 to 2 mg/mL of holotransferrin [8,41], 1 to 4 mg/mL of 55Fe [8,33,35,39,46], 20 to 40 µg/mL
of 59Fe bound to transferrin [31,40,42], nitrilotriacetate [46] or ascorbate [66], or 10 to 100 µM of
ferric ammonium citrate [6,32,55,57,83,93] for 24 h before to 48 h [8,31–33,39,40,42,46,55,66,83,87]
after transfection. Cells were lysed 4 to 72 h after iron loading [8,31,33,46,56]. Iron export
capacity was determined either by the measurement of radioactive Fe [8,31,33,35,39,40,42,46,56,66]
or ferritin concentration [6,8,11,32,33,35,41,42,55,57,83,87,93] in lysed cells [6,32,33,35,40,42,57,93] or
in the supernatant [8,11,31,33,35,39,46,56,83]. Results obtained in cells transfected with the variant
ferroportin were compared with results in untransfected cells and in cells transfected with wild-type
ferroportin. The effect of hepcidin on iron export capacity and the expression of the variant ferroportin
protein were analyzed. Experimental conditions are also not standardized; specific differences include:
(i) applied hepcidin concentration, which varied between 0.01 and 10 µM, and (ii) incubation times,
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which varied between 3 and 56 h [11,31–34,39,41,42,55,56,83,87,93]. The membrane expression of
variant ferroportin proteins was determined by surface biotinylation and Western blotting [8,39],
immunofluorescence [6,31–33,40,42,46,55–57,65,87] and confocal microscopy [11,34,41,83], or flow
cytometry [31,35,41,42,56]. These differences may be responsible for the variable results reported on
the effect of hepcidin on the membrane expression and iron export capacity of cells transfected with
WT ferroportin.
In a significant number of the tested variants, the effect of hepcidin was determined by means
of ferroportin expression and not by changes in iron export. Furthermore, in the vast majority of
the transfected LOF variants, the membrane expression of the protein was strongly reduced or even
absent, and therefore the effect of hepcidin is difficult to determine reliably. In a number of variants,
the inhibitory effect of hepcidin was tested at various concentrations of hepcidin and/or exposure
times, which resulted in a time and/or concentration dependent effect, ranging from hepcidin resistant
to more or less hepcidin sensitive [6,30,42,65]. Therefore it is not unthinkable that the same variant is
considered hepcidin resistant by one investigator and hepcidin sensitive by the other, depending on
the design of the applied assay.
So, large inter-assay variation may not only lead to conflicting results in ferroportin variants tested
in multiple studies, but also to reluctance to draw firm conclusions for data obtained in a single study.
In addition, our definition of LOF (i.e. a significant reduced iron transport in functional tests) and
hepcidin sensitivity (i.e. a significant reduction in iron transport or ferroportin expression in functional
assays upon the addition of hepcidin) may lead to discrepancies in the interpretation of the functional
characterization of some individual variants such as Gly204Arg and Arg296Gln, between us and the
authors of the original publication [51].
4.2.4. Lack of Concordance between Various In Silico Prediction Models
As illustrated in Table 4, the concordance between the three methods is poor, with a weak albeit
significant correlation between SIFT and Align-GVGD (r = 0.5441), polyphen2 and SIFT (r = 0.3832),
and polyphen2 and Align-GVGD (r = 0.3066).
4.3. Assessment of Pathogenicity of Ferroportin Variants on Molecular Level in Context of Current Knowledge
on the Function and Structure of Ferroportin
4.3.1. Ferroportin, the Protein, Its Variants, and Function: Current Knowledge
Ferroportin is a 571 amino acid cation transporter of the major facilitator superfamily
(MFS) encoded by the SLC40A1 gene [46,108–111]. It is the only known cellular iron exporter,
and primarily expressed in the basolateral membrane of duodenal enterocytes, macrophages,
and hepatocytes [108,110–112]. In the most widely accepted secondary structure, ferroportin comprises
12 helices located in 12 transmembrane (TM) domains bound via six extracellular (ES) and five
intracellular (IS) segments with a large intracellular loop between the sixth and seventh transmembrane
helix and intracellularly located N and C terminus [6,8,34,46,56,113]. Although the amount of
polymerization is still a matter of debate, most investigators assume that ferroportin is expressed
on the membrane as a dimer [6,34,35,55,114]. Available three-dimensional models are based on
comparison with ferroportin from other species with only 10-24% sequence homology and 40%
similarity [8,39,46,115]. Recent studies reveal an open-inward and an open-outward structure
with an intracellular and extracellular gate between the sixth and seventh transmembrane domain.
Extrapolating the experimental model to the human protein reveals that residues Asp84, Arg88,
Asp157, Asn174, Gln481, Glu486, and Arg489, which are located at IS1, IS2 and IS5, are important in
intracellular gate interaction, while the residues Phe44, Val48, Val 51, Leu58, Asp325, Thr329, Leu342,
and Phe520, which are located at TM1, TM12, ES1 and ES4, are involved in extracellular gate interaction
(Figure 3) [46,115]. It is postulated that intracellular iron is transported outside the cell, and that
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extracellular hepcidin is transported inside the cell through this gate via a so called “rocker-switch”
mechanism [46,115,116].
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Figure 3. The two-dimensional (2D) structure of ferroportin protein adapted from Liu and allace [6,56],
revealing 12 transmembrane helices and six extracellular and five intracellular segments. All the
variants described in this review are shown as hepcidin-resistant (pink), hepcidin-sensitive or neutral
(purple) and hepcidin conflicting/uncertain/unknown (red) GOF variants (squares). and hepcidin
resistant (light blue), hepcidin sensitive (dark blue), and hepcidin conflicting-uncertain-unknown
(green) LOF variants (dots), or non-classified variants (grey asterix).
Since sites containing an Asp, Glu, His, or Tyr residue are reported be involved in iron binding,
Asp39, Glu52, Tyr54, Asp181, Tyr318, Asp325, Tyr331, Tyr501, and Glu518 are potential iron binding
sites and Arg88, As157, Asn174, and Arg489 are involved in the intracellular gate interaction [46,115].
Functional studies revealed cation binding at Ser35, Asp39, Asn212, and Ser215 and site mutagenesis
studies suggest that Asp39 and Asp181 are essential iron binding sites [46,115]. The residues Arg88,
Ile152, and Asn174 are thought to be directly involved in iron egress [39].
Ferroportin-mediated cellular iron export is systemically regulated by the hepatocyte-derived
peptide hormone hepcidin. The way hepcidin binding inhibits iron eﬄux is not fully
elucidated [117–119]. Functional studies reveal the internalization of ferroportin upon hepcidin
binding with subsequent endosomal and lysosomal degradation resulting in the diminution of cellular
iron export, while three-dimensional (3D) structural studies suggest that hepcidin binding disrupts
the conformational transition into the intracellular gate with the subsequent inhibition of the access
of cytoplasmatic iron to the substrate binding-sites [115,120,121]. Site mutagenesis studies and the
exploration of various three dimensional models suggests that the Phe324, Cys326, Tyr333, Asp504,
and His507 residues are important binding and docking sites for hepcidin [32,39,46,115]. Recent
structural models indicate that these hepcidin binding residues are clustered in the extracellular gate
in the open-outward structure. Residues found to be involved in internalization include Tyr64, Gly80,
andAsn144, and the residues Lys229, Lys253, and Lys269 are present in the large intracellular loop, and
seem to be involved in the degradation of ferroportin [39,114,122].
In an effort to unravel the pathogenicity of ferroportin variants, we depicted the various variants
in the structure of ferroportin molecule. For the two-dimensional (2D) model (Figure 3), we adapted the
structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used
Pharmaceuticals 2019, 12, 132 17 of 29
the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet
Another Scientific Artificial Reality Application (YASARA) [123] and WHAT IF Twinset [124] programs.
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Figure 4. 3D model of ferroportin. (A). Overview. Ferroportin facing outward position. Top:
extracellular; Bottom: intracellular. (B). Localization of hepcidin-resistant GOF variants. View inside
the “channel” from extracellular to intracellular. Six (Cys326Tyr, Cys326Ser, Tyr333His, Tyr501Cys,
Asp504Asn, and His507Arg) of the seven residues of GOF hepcidin-resistant variants are located inside
the channel. The Ala69, Val72, Asn144, Gln182, and Ser338 residues are also located inside the channel.
However, these variants have conflicting or no data on hepcidin sensitivity. (C). Clustering of LOF
variants at the intracellular side of ferroportin. View inside the channel from extracellular to intracellular.
Red: GOF without or conflicting data about hepcidin sensitivity; Pink: GOF hepcidin-resistant variants;
Purple: GOF hepcidin-sensitive or neutral variants; Green: LOF without or conflicting data about
hepcidin sensitivity; Light blue: LOF hepcidin-resistant variants; Blue: LOF hepcidin-sensitive variants.
We used bacterial ferroportin for the 3D model (PDB file 5AYN).
Pharmaceuticals 2019, 12, 132 18 of 29
4.3.2. GOF Variants
We identified Tyr64Asn, Cys326Tyr, Cys326Ser, Tyr501Cys, Asp504Asn, and His507Arg as
definitely hepcidin-resistant GOF variants, and a co-culture of hepcidin with cells transfected with
these variants does not lead to the internalization of the ferroportin variant with maintained iron export
capacity and variant membrane expression [8,11,31–35,39–42,46]. Consequently, there is increased
iron export from enterocytes and macrophages leading to hepatocellular iron overload. Observations
in mice with the Cys326Ser variant reveal that increased dietary iron absorption is maintained by
the upregulation of the Duodenal cytochrome b (Dcytb) and Divalent Metal Transporter 1 (DMT1) at
the apical site of the enterocyte, which is likely to compensate for the pending intraenterocytic iron
depletion [125]. For Cys326Tyr, Cys326Ser, Tyr501Cys and Asp504Asn, the blocked internalization of
ferroportin on hepcidin exposure has been attributed to the impaired binding of hepcidin to ferroportin
in the extracellular gate, while for Tyr64Asn and His507Arg—of which the location in relation to this gate
varies between the available models—the impaired ubiquitination of hepcidin, which was most likely
due to interference with conformation, is the most likely mechanism (Figure 4B) [30]. The Tyr333Ala,
Tyr333His (both hepcidin-resistant variants in a functional test) and Tyr333Phe (hepcidin-sensitive)
GOF variants display both membrane localization and intact iron export, but impaired ubiquitination
after normal hepcidin binding; however, there are no data on configural changes due to presence of
these variants [30,45].
The Ile180Thr, Thr230Asn, Met266Thr, Leu345Phe, Ile351Val, Pro443Leu, and Arg561Gly were
designated as hepcidin-sensitive GOF variants. In functional studies, the iron export capacity, hepcidin
uptake, and hepcidin-induced reduction of the cell surface expression of these variants were comparable
with WT ferroportin [8,11,31,35]. None of these variants are located at residues that are known to be
involved in hepcidin binding, ferroportin ubiquitination, or iron binding/egress. Notwithstanding
that these seven variants behaved as WT ferroportin in functional studies and are located at residues
without an established functional role, the reported 16 patients had otherwise unexplained mild iron
overload, which was reflected by a median TSAT of 42.5% and serum ferritin concentration of 980 µg/l.
Nevertheless, the pathogenicity of the variants may be questioned, and therefore, the variants may as
well be classified as neutral [8].
4.3.3. LOF Variants
Except for Leu129 and Gly323, the residues of the alterations that are associated with LOF
variants are located at the intracellular site of the molecule, especially in the IS1, IS2, and IS5
(Figure 3) structures, which are involved in the formation of the intracellular gate responsible for
iron transport (Figure 4C) [115]. In transfected cells, the majority of LOF variants are reported to be
located intracellularly or have reduced membrane expression, although the data are not consistent
for some variants (Table 2). Alteration in these residues may lead to conformational changes due to
improper folding with mislocalization and disrupted intracellular gate formation. The substitution
of Arg by Gly at residue 88 may lead to direct impaired iron handling with disrupted iron egress.
That four hepcidin-sensitive variants display more or less intact membrane expression suggests
intact extracellular gate formation enabling hepcidin binding. It was recently demonstrated that the
hepcidin-sensitive LOF variant Arg178Gln, which is properly localized on the cellular membrane with
disappearance after hepcidin exposure, is likely to form a non-covalent interaction between Arg178
and Asp473, which are located on the N and C lobe, respectively. This interaction may lead to a loss of
stabilization of the open-outward conformation that is needed to preserve iron egress [84]. Residues of
the four hepcidin-resistant LOF variants are not involved in hepcidin binding, so hepcidin resistance is
likely to result from conformational changes in the extracellular gate, even though these variants have
demonstrable but reduced membrane expression.
Overall, we conclude from that for most variants, clinical, functional, molecular, and in silico
assessments of pathogenicity are not fully concordant, complicating the assessment of their likelihood
of being the disease-causing variant (Table 4). For instance, the hepcidin-resistant GOF variants
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Tyr64Asn Cys326Ser, Cys326Tyr, Asp504Asn, and His507Arg are benign in two of the predicting
in silico models, while clearly damaging variants in the three applied prediction models such as
Leu129Pro and Ile180Thr were clinically likely to be benign. On the other hand, six out of the seven
hepcidin-sensitive GOF variants had a low likelihood for pathogenicity both on clinical and molecular
ground as well as in the predicting models.
4.4. Is the Mode of Iron Overload in LOF Variants Related to a Difference in Ferroportin Expression and
Activation between Enterocytes and Macrophages?
Despite clear differences in iron distribution between patients with GOF and LOF variants, hepatic
iron content and iron that is needed to be removed by phlebotomy to obtain a normalized iron
phenotype are not found to differ, which might suggest that the total amount of absorbed iron in
GOF and LOF patients is similar. Therefore, we hypothesize that in enterocytes, all the pathogenic
ferroportin variants are associated with increased iron transport, irrespective of the (in vitro) function
of the variant, while iron transport in macrophages and thereby the mode of systemic iron distribution
is dependent on variant function. For patients with LOF variants, this hypothesis includes iron export
being relatively decreased in macrophages, and being increased in enterocytes.
Ferroportin knock-out mice are not viable [110]. Mice with mono-allelic expression of wild-type
(WT) ferroportin [111] and TMPRSS6 knock-out mice with subsequent reduced ferroportin expression
on enterocytic membrane, develop iron deficiency anemia with intra-enterocytic iron retention [126]
and patients with TMPRSS6 variants develop Iron Refractory Iron Deficiency Anemia (IRIDA) due
to impaired intestinal iron absorption [127–129]. In contrast, patients heterozygous for LOF variants,
which fail to export iron in functional tests, do not develop iron deficiency anemia; instead, they
develop systemic, predominantly reticuloendothelial iron overload with limited but consistent proof
for iron depletion in the enterocytes [79,88].
It has been recently suggested that differences in amount of intracellular iron turnover between
enterocytes and macrophages may influence iron export capacity of these cells in patients with
ferroportin disease due to LOF variants [130]. The monoallelic-expressed WT ferroportin protein
would be sufficient to preserve iron export in cells with low iron turnover, such as enterocytes,
but insufficient to maintain iron export capacity in cells with high iron turnover, such as splenic
and hepatic macrophages, with subsequent intracellular iron retention in these cells. However, this
hypothesis is insufficient to explain the state of iron overload. Functional consequences of a variant
leading to the designation LOF is foremost established in HEK293T, which is a human embryonic
kidney cell line, and are in accordance with events as observed in macrophages but fail to elucidate
events that must be present in the enterocytes. So, HEK293T cells might not be the most appropriate
experimental cell line to predict the functional consequences of at least LOF variants.
Experimental data provide evidence for differences in ferroportin expression and the activation
between enterocytes and macrophages. Ferroportin is expressed on the enterocytic basolateral
membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that
the mode of hepcidin-induced internalization differs in macrophages [120,132].
Intracellular transcription and the translation of SLC40A1 is primarily regulated by iron and
oxygen in enterocytes and heme and iron in macrophages, [113,131,133]; also, the modulatory capacity
by the iron-regulatory protein-iron-responsive element (IRP-IRE) system may differ between both
cell types [134–138]. After iron egress from enterocytes, ferrous iron is oxidized by membrane-bound
hephaestin, co-located with ferroportin, while ferrous iron release from macrophages is oxidized by
circulating ceruloplasmin [139,140].
Ferroportin expression differs between enterocytes and macrophages in response to systemic
regulatory stimuli such as erythropoietin and hepcidin, changes in iron state, and inflammation
(hepcidin independent) in experimental animals, as well as in isolated cell cultures [132,141–152].
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Taken together, these experimental data suggest a regulation difference of ferroportin production
and activation, between enterocytes and macrophages [153]. However, the extrapolation of results
obtained from experimental models to physiology must be done with caution.
5. Conclusions
We analyzed 60 low-frequency missense variants in the coding sequence of the ferroportin gene
reported over the past 20 years, which has been assumed to be responsible for iron overload in
individual patients reported in the English literature with or without subsequent evaluation of the
relatives. The clinical and laboratory features of the patients (phenotype) with these ferroportin variants
were correlated with data on variant properties in functional in vitro tests, which were available for 80%
of the variants. However, the reported clinical features are often incomplete and functional tests are
artificial, not standardized, or unvalidated, which impedes the interpretation of the correlation between
the functional properties and phenotype. The establishment of variant pathogenicity is hampered by a
lack of sufficiently reported data regarding the presence of iron-modifying confounders and because the
outcomes of available in silico prediction models is limited in the absence of a fully elucidated structure
and function. Therefore, it is likely that not all reported variants are indeed pathogenic, but from the
available data, it is nearly impossible to accurately establish the pathogenicity of individual variants.
Notwithstanding these limitations, we can conclude that ferroportin disease is a heterogeneous iron
overload disorder. Clinical symptoms are non-specific, and mostly consist of fatigue and arthralgia.
At presentation, patients are generally middle aged with strongly elevated ferritin concentrations and
mildly elevated TSAT and iron concentrations. Iron parameters and the severity of iron overload
show considerable inter-individual variation and are also related to gender, age, and type of variant.
The mode of organ iron distribution is primarily determined by the effect of ferroportin variants on
macrophage iron export, which is comparable with that observed in functional in vitro studies. LOF
variants are associated with macrophage iron retention with a high serum ferritin and low to normal
TSAT, in contrast to GOF variants, which are associated with high TSAT and hepatocellular iron
deposition. These distinct phenotypes are typically present in patients with hepcidin-resistant variants.
Patients with GOF variants had a higher prevalence and higher grade of hepatic fibrosis, indicating
that parenchymal iron deposition is more toxic than macrophage iron overload. This corroborates
the notion that high TSAT facilitates parenchymal iron deposition, which is considered to be more
toxic than macrophage iron overload [154]. On the other hand, with regard to toxicity in macrophages,
it has been stated that macrophage iron overload is resistant to iron withdrawal, and that iron-loaded
Kupffer cells may contribute to the development of hepatic fibrosis and even carcinogenesis [106].
Since iron distribution patterns and clinical features of patients with hepcidin-resistant GOF
variants are indistinguishable from patients with other types of HH, we support the proposition to
categorize these variants as ferroportin-associated HH, and to confine the entity ferroportin disease
to patients with LOF variants [116]. For both entities, repeated phlebotomies to normalize the iron
parameters in order to prevent organ damage remain the mainstay of treatment. Although we found
no increased intolerance to phlebotomy in patients with LOF variants, we advocate for the regular
determination of Hb levels during the phlebotomy program, especially in patients with hepcidin-
resistant LOF variants, to avoid the occurrence of early anemia.
The pathophysiology, especially of the LOF variants, is only partially understood. The
iron handling within the various human cell types is not fully clarified, and the mechanisms
by which ferroportin transports iron and is degraded are still not fully elucidated. To improve
patient management, there is an unmet need for a better understanding of yet unresolved
issues on the pathophysiology. A global registry, with a standardized diagnostic work-up and
evaluation of the clinical, biochemical, radiological, and histological features of the liver and
spleen, is needed, such as the registry sponsored by the European Association for the Study of
the Liver (EASL) (http://non-hfe.com/) [155], a collaboration between various European Expert centers,
or registries launched by the European Reference Network (ERN) of rare Hematological Disorders
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(EUROBLOODNET). Also, the histologic and molecular examination of enterocytes in duodenal
biopsies of these patients by assessing iron content, as well as the expression of iron storage and
transport proteins, will add to a better understanding of the iron handling. The secondary and tertiary
structure of ferroportin as well as the identification of residues that are involved in hepcidin binding,
ferroportin ubiquitination, and iron transport need to be further elucidated. Finally, the standardization
of validated functional tests, which are preferably performed in human-derived enterocytic and
macrophagic cell lines, will enable exploring iron transport and the modulating effect of hepcidin
of known and yet unclassified variants, and will improve our insights of the pathophysiology of
ferroportin disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/12/3/132/s1,
Figure 1S: Relation between age and serum iron/TSAT/ferritin, Table 1S: Characteristics and iron parameters of
probands versus probands’ relatives, Table 2S: Phenotypical features by the reported presence of hereditary HFE
and non-HFE iron overload conditions, Table 3S: Phenotypical features by the reported current use of alcohol,
Table 4S: Phenotypical features of patients with functional LOF ferroportin variant by hepcidin sensitivity, Table 5S:
Phenotypical features by hepcidin resistant GOF and LOF ferroportin variants.
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